Protocol Ledger

NCT06058377 · Phase III · RECRUITING

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Interventional Phase III clinical trial protocol NCT06058377 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-27 Enrollment: 3,680 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06058377
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)3,680 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06058377
Protocol FieldVerified Registry Value
NCT IdentifierNCT06058377
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment3,680 participants (ESTIMATED)
Registered Start Date2023-11-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI